<DOC>
	<DOCNO>NCT00901615</DOCNO>
	<brief_summary>The purpose study determine recommend dose ( RD ) lenalidomide ( Revlimid ) administer association R-CHOP ( rituximab ( R ) , cyclophosphamide , doxorubicin , vincristine prednisone ) .</brief_summary>
	<brief_title>Lenalidomide R-CHOP B-cell Lymphoma</brief_title>
	<detailed_description>The study dose escalation study lenalidomide ( Revlimid ) administer orally 14 day combination fix dos rituximab ( R ) , cyclophosphamide , doxorubicin , vincristine prednisone ( CHOP ) administer every 3 week ( R-CHOP 21 ) patient B-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients one follow Bcell Lymphoma , CD 20 positive : Mantle cell , Marginal zone , follicular Histological transformation low grade high grade Diffuse large B cell Aged 18 70 year WHO performance status 0 , 1 2 Signed inform consent Life expectancy ≥ 90 day ( 3 month ) . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 25 mIU/mL 3 day start study drug must either commit continued abstinence heterosexual intercourse begin one acceptable method birth control , least 4 week start take lenalidomide . FCBP must also agree monthly pregnancy test must counsel minimum every 4 week pregnancy precaution risk fetal exposure . Men must agree father child agree use condom partner child bear potential . Men must also counsel minimum every 4 week pregnancy precaution risk fetal exposure . † A female patient consider childbearing potential unless meet least one follow criterion 1 ) Age &gt; 50 year naturally amenorrhoeic &gt; 1 year ( amenorrhoea follow cancer therapy rule childbearing potential ) ; 2 ) Premature ovarian failure confirm specialist gynaecologist 3 ) Previous bilateral salpingooophorectomy , hysterectomy , 4 ) XY genotype , turner syndrome , uterine agenesis . Previous treatment immunotherapy chemotherapy except : Chlorambucil Cyclophosphamide per o alone less 6 month , stop one year inclusion Rituximab alone less three month , stop one year inclusion Previous radiotherapy except localized one lymph node area Other type lymphoma : Burkitt , T cell , lymphocytic , CD 20 negative Central nervous system meningeal involvement Contraindication drug contain chemotherapy regimen HIV disease , active hepatitis B C Any serious active disease comorbid medical condition ( accord investigator 's decision ) Any follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) . Platelet count &lt; 100,000/mm3 ( 100 x 109/L ) . Serum SGOT/AST SGPT/ALT 5.0 x upper limit normal ( ULN ) . Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) , except case hemolytic anemia . Calculated creatinine clearance ( CockcroftGault formula ) &lt; 50 mL /min Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactating female . Prior ≥ Grade 3 allergic reaction/hypersensitivity thalidomide . Prior ≥ Grade 3 rash desquamating ( blister ) rash take thalidomide . Subjects ≥ Grade 2 neuropathy . Prior use lenalidomide . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>gela</keyword>
</DOC>